| Literature DB >> 28088537 |
Rebekah M Ahmed1, Muireann Irish2, Janet van Eersel3, Arne Ittner3, Yazi D Ke3, Alexander Volkerling3, Julia van der Hoven3, Kimi Tanaka3, Tim Karl4, Michael Kassiou5, Jillian J Kril6, Olivier Piguet7, Jürgen Götz8, Matthew C Kiernan9, Glenda M Halliday10, John R Hodges11, Lars M Ittner12.
Abstract
Frontotemporal dementia (FTD) is the second most common cause of young onset dementia. It is increasingly recognized that there is a clinical continuum between FTD and amyotrophic lateral sclerosis (ALS). At a clinical, pathological and genetic level there is much heterogeneity in FTD, meaning that our understanding of this condition, pathophysiology and development of treatments has been limited. A number of mouse models focusing predominantly on recapitulating neuropathological and molecular changes of disease have been developed, with most transgenic lines expressing a single specific protein or genetic mutation. Together with the species-typical presentation of functional deficits, this makes the direct translation of results from these models to humans difficult. However, understanding the phenotypical presentations in mice and how they relate to clinical symptomology in humans is essential for advancing translation. Here we review current mouse models in FTD and compare their phenotype to the clinical presentation in patients.Entities:
Keywords: Amyotrophic lateral sclerosis; Behavioural neurology; Frontotemporal dementia; Mouse; Transgenic
Mesh:
Year: 2017 PMID: 28088537 DOI: 10.1016/j.neubiorev.2017.01.004
Source DB: PubMed Journal: Neurosci Biobehav Rev ISSN: 0149-7634 Impact factor: 8.989